, /PRNewswire/ -- The global allergy immunotherapies market size is estimated to grow by .18 billion from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of almost 9.
62% during the forecast period. For comprehensive forecast and historic data on regions, market segments, customer landscape, and companies- The global allergy immunotherapies market faces challenges due to unclear allergy indications pathogenesis and diagnosis. Current methods include blood tests, skin tests, and patch tests.
Research is ongoing to develop novel diagnostic therapies, leading to earlier diagnosis and effective treatment. Siemens Healthcare's IMMULITE 2000 XPi Immunoassay system aids in diagnosing various medical conditions, including allergies. New allergens identification will lead to better immunotherapies and market growth.
The Allergy Immunotherapies Market is currently experiencing significant growth due to the increasing prevalence of allergies worldwide. Allergy immunotherapies, also known as allergy shots or subcutaneous immunotherapy (SCIT), and sublingual immunotherapy (SLIT), are gaining popularity as effective treatments for various allergies. These therapies work by gradually exposing the body to allergens, helping the immune system build a tolerance.
Companies are investing in research and development to improve the efficacy and accessibility of these therapies. Allergy shots are given in a healthcare provider's office, while SLIT can be taken at home. B.
